Crinetics Pharmaceuticals, Inc. (CRNX) News

Crinetics Pharmaceuticals, Inc. (CRNX): $16.23

-0.73 (-4.30%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter CRNX News Items

CRNX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

CRNX News Highlights

  • For CRNX, its 30 day story count is now at 6.
  • Over the past 14 days, the trend for CRNX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about CRNX are RARE, SNAP and MA.

Latest CRNX News From Around the Web

Below are the latest news stories about Crinetics Pharmaceuticals Inc that investors may wish to consider to help them evaluate CRNX as an investment opportunity.

Crinetics Pharmaceuticals Stock Is Showing Strong Insider Interest

Clinical-stage pharmaceutical company Crinetics Pharmaceuticals Inc. (CRNX) has seen a key corporate insider snap up shares recently. Regulations require corporate insiders to make their trading activity public, and their actions could signal to investors that now is the time to get in on the action. In the last 12 days, corporate insider Perceptive Advisors LLC, which owns a more than 10% stake in the company, has bought $5 million worth of Crinetics shares. (See Crinetics stock analysis on TipRanks) On March 31, H. C. Wainwright analyst Douglas Tsao reiterated a Buy rating on the stock with a $30 price target (81.3% upside potential).

Kailas Salunkhe on TipRanks | April 21, 2021

Crinetics Pharmaceuticals Announces Closing of Common Stock Offering

SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today that it has closed its previously announced underwritten follow-on offering of 4,562,044 shares of its common stock at a price to the public of $16.44 per share. The gross proceeds to Crinetics from the offering, before deducting the underwriting discounts and commissions and other offering expenses, were approximately $75.0 million. Investors in the offering included Deep Track Capital, Bain Capital Life Sciences, and Driehaus Capital Management, with participation from other new and existing stockhol...

Yahoo | April 12, 2021

What Type Of Shareholders Own The Most Number of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares?

A look at the shareholders of Crinetics Pharmaceuticals, Inc. ( NASDAQ:CRNX ) can tell us which group is most powerful...

Yahoo | April 12, 2021

Crinetics Pharma raises $75M via equity offering

Crinetics Pharmaceuticals (CRNX) has priced its public offering of ~4.6M common shares at $16.44/share, for expected gross proceeds of ~$75M. Net proceeds will be used to fund the development of paltusotine and other R&D programs, for working capital and general corporate purposes. SVB Leerink is acting as sole bookrunning manager.Closing...

Seeking Alpha | April 8, 2021

Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock

SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today the pricing of an underwritten public offering of 4,562,044 shares of its common stock at a price to the public of $16.44 per share. All of the shares to be sold in the offering are being sold by Crinetics. The gross proceeds to Crinetics from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $75.0 million. The offering is expected to close on or about April 12, 2021, subject to the satisfaction of customary closing c...

Yahoo | April 7, 2021

Crinetics Pharmaceuticals to Host Webcast and Conference Call to Discuss 2021 Clinical Plans and Fourth Quarter and Full Year 2020 Financial Results

Webcast and conference call to take place on Tuesday, March 30, 2021 at 4:30 p.m. ETSAN DIEGO, March 24, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that it will host a webcast and conference call on Tuesday, March 30, 2021 at 4:30 p.m. ET to discuss its 2021 clinical plans and financial results for the fourth quarter and full year 2020. To access the webcast, please visit this link to the event. To participate by phone, please dial 877-407-0789 (domestic) or 201-689-8562 (international) and refer to conference ID 13717687. Following the live event, the archived we...

Yahoo | March 24, 2021

Crinetics Pharmaceuticals Pipeline Progress on Display at ENDO 2021

Oral and Late-breaker Presentations Selected on the Company’s ACTH Antagonist and Congenital HI ProgramsSAN DIEGO, March 22, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today provided details of four presentations that were made at the Endocrine Society’s annual ENDO 2021 congress on the company’s product pipeline. A late-breaking e-poster and oral presentation provided details of the preclinical findings supporting the company’s development of CRN04894 and CRN04777. In addition, a summary of the previously announced ACROBAT Edge Phase 2 results as well as details of an improved t...

Yahoo | March 22, 2021

Crinetics Pharmaceuticals Lead ACTH Antagonist for Congenital Adrenal Hyperplasia and Cushing’s Disease (CRN04894) Advances into Phase 1 Study

SAN DIEGO, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that CRN04894, the company’s lead adrenocorticotropic hormone (ACTH) antagonist for the treatment of diseases associated with excess ACTH such as Cushing’s disease and congenital adrenal hyperplasia (CAH), has advanced into the clinic. Based on encouraging preclinical results, Crinetics has initiated a double-blind, randomized, placebo-controlled Phase 1 study of this orally administered, nonpeptide small molecule drug candidate in healthy volunteers. This study will assess the safety and tolerability ...

Yahoo | February 4, 2021

Crinetics Pharmaceuticals Advances CRN04777 for Congenital Hyperinsulinism into Phase 1 Study

Phase 1 study is designed to provide clinical proof-of-concept by taking advantage of established methods in endocrinologySAN DIEGO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the initiation of a Phase 1 study of CRN04777, an oral, nonpeptide somatostatin receptor type 5 (SST5) agonist being developed as a treatment for congenital hyperinsulinism (HI). Congenital HI is a rare genetic disease associated with dysregulated insulin production in which excess insulin produces life-threatening hypoglycemia (low blood glucose) beginning at birth. The purpose of t...

Yahoo | February 3, 2021

Crinetics Pharmaceuticals to Review 2020 Accomplishments and Provide 2021 Plans at 39th Annual J.P. Morgan Healthcare Conference

\- Paltusotine planned to advance to a pivotal Phase 3 trial in acromegaly in H1 2021 - \- Initiation of Phase 1 proof-of-concept study evaluating CRN04894 for the treatment of congenital adrenal hyperplasia and Cushing’s disease expected in January 2021 -\- Initiation of Phase 1 proof-of-concept study evaluating CRN04777 for the treatment of congenital hyperinsulinism expected in February 2021 -SAN DIEGO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that company management will participate in the 39th annual J.P. Morgan Healthcare Conference, which is taking pla...

Yahoo | January 6, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5588 seconds.